Bausch Health Companies Inc.
Bausch Health Companies Inc. is registered with the U.S. Securities and Exchange Commission (CIK 0000885590, SEC file number 001-14956) as a corporation organized under the laws of the State of New Jersey, USA. The company’s principal executive offices are located at 2150 St. Elzear Blvd. West, Laval, Quebec, Canada H7L 4A8. Its common shares trade on the New York Stock Exchange and the Toronto Stock Exchange under the ticker symbol BHC. Bausch Health Companies Inc. operated under the name Valeant Pharmaceuticals International, Inc. until it changed its corporate name effective 13 July 2018. A Quebec or New Jersey company registration number was not identified in the primary sources reviewed for this profile.
Bausch Health Companies Inc. is a diversified specialty pharmaceutical and medical technology company. Following the May 2022 initial public offering of its former eye-health division, Bausch + Lomb Corporation, the company reports its ongoing operations across four segments: Bausch + Lomb, Salix, International and Solta Medical. The Salix segment develops and markets prescription gastrointestinal products, including rifaximin-based therapies. The Solta Medical segment supplies energy-based aesthetic medical devices. The International segment sells branded and branded-generic pharmaceutical products in markets outside the United States and Canada. The Bausch + Lomb segment covers vision-care, surgical and pharmaceutical eye-health products sold through the separately listed Bausch + Lomb Corporation.
For the year ended 31 December 2025, Bausch Health Companies Inc. reported consolidated revenues of 10,266 million US dollars, an increase of 7 percent on a reported basis from 9,625 million US dollars in 2024, according to results the company announced on 18 February 2026. Growth was attributed to its Bausch + Lomb, Salix, Solta Medical and International segments. As disclosed in its 2026 SEC filings, Bausch Health Companies Inc. continued to hold an indirect majority equity interest of approximately 87 percent in Bausch + Lomb Corporation, which trades separately on the New York Stock Exchange and the Toronto Stock Exchange under the ticker BLCO. The companies have stated an intention to complete a full separation of the two businesses, including a possible sale of the retained stake, but as of the sources reviewed had given no assurance on the timing or terms of any such transaction.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
5
Shareholders of Bausch Health Companies Inc.
Bausch Health Companies Inc. is a publicly traded company listed on the New York Stock Exchange and the Toronto Stock Exchange under the ticker BHC. Zavia’s on-file registry data identifies five disclosed institutional holders of ordinary shares as verified on 2 August 2026: Vanguard Group Inc. (approximately 5.55 percent), Hudson Bay Capital Management LP (approximately 2.60 percent), Schwab Strategic Trust – Schwab Fundamental International Equity ETF (approximately 0.54 percent), Schwab Strategic Trust – Schwab International Small-Cap Equity ETF (approximately 0.34 percent), and SPDR Index Shares Funds – SPDR Portfolio Developed World ex-US ETF (approximately 0.19 percent). These figures were reported as at the stated verification date and are not certain to remain current. This is a major-shareholders-only snapshot: for a NYSE- and TSX-listed company of this size, most outstanding shares are held through custodians, index funds, other institutional managers and retail investors that are not individually itemised in the data reviewed.
Data availability
Classification: Major shareholders only. The disclosed holdings represent a subset of institutional positions captured as at 2 August 2026 rather than a complete public shareholder register. No individual ultimate beneficial owner was identified, consistent with a widely held, exchange-listed issuer with no single controlling shareholder disclosed in the sources reviewed.
Sources
- Zavia on-file institutional shareholder data, verified 2 August 2026
- New York Stock Exchange and Toronto Stock Exchange listing records for ticker BHC
| Shareholder | Type | Holding | Source Document |
|---|---|---|---|
| Vanguard Group Inc | 5.6% | Registraire des entreprises du Québec (REQ) | |
| Hudson Bay Capital Management Lp | 2.6% | Registraire des entreprises du Québec (REQ) | |
| SCHWAB STRATEGIC TRUST-Schwab Fundamental International Equity ETF | 0.5% | Registraire des entreprises du Québec (REQ) | |
| SCHWAB STRATEGIC TRUST-Schwab International Small-Cap Equity ETF | 0.3% | Registraire des entreprises du Québec (REQ) | |
| SPDR INDEX SHARES FUNDS-SPDR Portfolio Developed World ex-US ETF | 0.2% | Registraire des entreprises du Québec (REQ) |
Officers
19
Directors and officers of Bausch Health Companies Inc.
Zavia’s on-file registry data lists 19 officer entries for Bausch Health Companies Inc., of which the entries reviewed are recorded with an active work status and no resignation date. Current senior officers identified in this data include Jean-Jacques Charhon (Executive Vice President and Chief Financial Officer), Tage Ramakrishna, M.D. (Chief Medical Officer and President of Research and Development), Steven Lee (Senior Vice President, Controller and Chief Accounting Officer), Josh Coyle (Senior Vice President of Sales, Salix), and Donald Pearl (Senior Vice President, Ortho Dermatologics). Jean-Jacques Charhon’s appointment as Executive Vice President and Chief Financial Officer in August 2024 is independently confirmed by the company’s own SEC filings; a precise appointment date within that month was not confirmed in the sources reviewed. Bausch Health Companies Inc.’s Chief Executive Officer and its board of directors are disclosed separately in the company’s 2026 annual proxy statement (SEC Form DEF 14A) but are not included among the on-file officer entries reviewed for this profile. Nationality is not disclosed for any officer in the available data. All reviewed entries show Canada as the address-country field; this is a correspondence or registry address field only and must not be read as nationality or country of residence.
Recent officer changes
Jean-Jacques Charhon joined Bausch Health Companies Inc. as Executive Vice President and Chief Financial Officer in August 2024, as confirmed by the company’s SEC filings and investor communications; no further verified appointment, resignation or role change was identified in the sources reviewed.
Data availability
Classification: Partial. The on-file registry entries identify current senior officers but do not disclose appointment or resignation dates, occupation distinct from role, or nationality, and do not include the company’s board of directors, which is disclosed separately in SEC proxy filings.
Sources
- Zavia on-file officer registry data for Bausch Health Companies Inc.
- Bausch Health Companies Inc. Form DEF 14A (2026 proxy statement), SEC EDGAR CIK 0000885590
Registry feed — rows exactly as filed with Registraire des entreprises du Québec (REQ), including entries the profile above does not cover.
Group Structure
Group structure of Bausch Health Companies Inc.
Bausch Health Companies Inc. is the ultimate parent of its corporate group; no external parent company was identified in the sources reviewed. Its most significant verified corporate relationship is with Bausch + Lomb Corporation, its former eye-health division, which completed an initial public offering on 10 May 2022 in which a wholly owned subsidiary of Bausch Health Companies Inc. sold 35,000,000 common shares. Bausch + Lomb Corporation now trades separately on the New York Stock Exchange and the Toronto Stock Exchange under the ticker BLCO and files its own reports with securities regulators. As disclosed in Bausch Health Companies Inc.’s 2026 SEC filings, the company continued to hold an indirect interest of approximately 87 percent of Bausch + Lomb Corporation’s outstanding common shares, making Bausch + Lomb Corporation a majority-owned, separately listed subsidiary rather than a fully divested former affiliate. The companies have publicly stated an intention to pursue a full separation, including a possible sale of the remaining stake, but had not completed such a transaction and gave no assurance on timing as of the sources reviewed. Beyond this relationship, Zavia’s on-file corporate-linkage data records no other verified parent, subsidiary or sister-company relationship for Bausch Health Companies Inc.; the group’s other operating subsidiaries, including entities operating the Salix and Solta Medical businesses, were not individually confirmed against a primary registry source for this profile.
Recent structural changes
The initial public offering of Bausch + Lomb Corporation, completed 10 May 2022, separated the eye-health business into an independently listed company while Bausch Health Companies Inc. retained majority ownership; based on the company’s most recent 2026 SEC filings, no further sale or completed separation of the retained Bausch + Lomb Corporation stake had occurred.
Data availability
Classification: Partial. The Bausch + Lomb Corporation relationship is verified through SEC filings and official investor communications, but the group’s other operating subsidiaries are not individually confirmed in the sources reviewed for this profile.
Sources
- Bausch Health Companies Inc., Form 10-K for fiscal year 2022, SEC EDGAR CIK 0000885590
- Bausch Health and Bausch + Lomb Corporation, joint announcement of closing of Bausch + Lomb’s initial public offering, 10 May 2022
- Bausch Health Companies Inc. 2026 SEC quarterly filings (Form 10-Q), SEC EDGAR CIK 0000885590
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What is Bausch Health Companies Inc.?
Bausch Health Companies Inc. is a New Jersey-incorporated, diversified specialty pharmaceutical and medical technology company listed on the New York Stock Exchange and the Toronto Stock Exchange under the ticker BHC, with principal executive offices in Laval, Quebec, Canada.
Where is Bausch Health Companies Inc. incorporated?
According to its SEC filings, Bausch Health Companies Inc. is a corporation organized under the laws of the State of New Jersey, USA. Its principal executive offices are in Laval, Quebec, Canada, which is the company's operating headquarters rather than its state of incorporation.
What was Bausch Health Companies Inc.'s previous name?
Bausch Health Companies Inc. was known as Valeant Pharmaceuticals International, Inc. until it changed its corporate name, effective 13 July 2018.
What is Bausch Health Companies Inc.'s stock ticker symbol?
Bausch Health Companies Inc. trades under the ticker symbol BHC on both the New York Stock Exchange and the Toronto Stock Exchange.
Is Bausch Health Companies Inc. the same company as Bausch + Lomb Corporation?
No. Bausch Health Companies Inc. and Bausch + Lomb Corporation are separate, separately listed legal entities. Bausch + Lomb Corporation was the eye-health division of Bausch Health until its May 2022 initial public offering, and Bausch Health Companies Inc. continued to hold an indirect majority stake of approximately 87 percent in Bausch + Lomb Corporation as disclosed in its 2026 SEC filings.
Does Bausch Health Companies Inc. still own Bausch + Lomb Corporation?
Yes, in large part. As of Bausch Health Companies Inc.'s 2026 SEC filings, the company continued to hold an indirect interest of approximately 87 percent of Bausch + Lomb Corporation's outstanding common shares. A full separation, including a possible sale of the remaining stake, has been discussed publicly but had not been completed as of the sources reviewed.
What business segments does Bausch Health Companies Inc. operate?
Bausch Health Companies Inc. reports its operations across four segments: Bausch + Lomb, Salix, International and Solta Medical, covering eye health, gastrointestinal pharmaceuticals, international branded and branded-generic pharmaceuticals, and aesthetic medical devices respectively.
What was Bausch Health Companies Inc.'s revenue in 2025?
Bausch Health Companies Inc. reported consolidated revenues of 10,266 million US dollars for the year ended 31 December 2025, an increase of 7 percent on a reported basis from 9,625 million US dollars in 2024, according to results announced on 18 February 2026.
Who is the Chief Financial Officer of Bausch Health Companies Inc.?
Jean-Jacques Charhon serves as Executive Vice President and Chief Financial Officer of Bausch Health Companies Inc., a role he assumed in August 2024 according to the company's SEC filings.
What is Bausch Health Companies Inc.'s company registration number?
A specific Quebec or New Jersey company registration number was not identified in the primary government or securities sources reviewed for this profile.
Who are the major shareholders of Bausch Health Companies Inc.?
Zavia on-file data identifies institutional holders including Vanguard Group Inc. (approximately 5.55 percent) and Hudson Bay Capital Management LP (approximately 2.60 percent), as verified on 2 August 2026. This is a major-shareholders-only snapshot rather than a complete shareholder register.
Does Bausch Health Companies Inc. have a controlling shareholder or ultimate beneficial owner?
No individual ultimate beneficial owner has been identified in the sources reviewed. Bausch Health Companies Inc. is a widely held, exchange-listed company with no single controlling shareholder disclosed.
Where are Bausch Health Companies Inc.'s executive offices located?
Bausch Health Companies Inc.'s principal executive offices are at 2150 St. Elzear Blvd. West, Laval, Quebec, Canada H7L 4A8.
What industry classification applies to Bausch Health Companies Inc.?
Bausch Health Companies Inc. is classified under SIC code 2834, Pharmaceutical Preparations, in its SEC filings, reflecting its specialty pharmaceutical and medical device operations.